Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Evaluation of pooling of samples for testing SARS-CoV- 2 for mass screening of COVID-19.

Tytuł:
Evaluation of pooling of samples for testing SARS-CoV- 2 for mass screening of COVID-19.
Autorzy:
Mahmoud SA; Biogenix G42 lab, Abu Dhabi, UAE. .
Ibrahim E; Biogenix G42 lab, Abu Dhabi, UAE.
Thakre B; Biogenix G42 lab, Abu Dhabi, UAE.
Teddy JG; Biogenix G42 lab, Abu Dhabi, UAE.
Raheja P; Biogenix G42 lab, Abu Dhabi, UAE.
Ganesan S; G42 Health care, Abu Dhabi, UAE.
Zaher WA; G42 Health care, Abu Dhabi, UAE.
Źródło:
BMC infectious diseases [BMC Infect Dis] 2021 Apr 17; Vol. 21 (1), pp. 360. Date of Electronic Publication: 2021 Apr 17.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2001-
MeSH Terms:
COVID-19/*diagnosis
COVID-19 Testing/*methods
Mass Screening/*methods
Clinical Laboratory Techniques ; Humans ; Pandemics ; SARS-CoV-2 ; Sensitivity and Specificity ; Viral Load
References:
Wellcome Open Res. 2020 Aug 6;5:186. (PMID: 33134555)
Clin Microbiol Infect. 2020 Dec;26(12):1687.e1-1687.e5. (PMID: 32919074)
JAMA. 2020 May 19;323(19):1967-1969. (PMID: 32250394)
Epidemiol Infect. 2020 Aug 06;148:e183. (PMID: 32758313)
BMJ. 2020 Feb 18;368:m641. (PMID: 32071063)
J Infect Dev Ctries. 2020 Oct 31;14(10):1136-1137. (PMID: 33175708)
Am J Clin Pathol. 2020 May 5;153(6):715-718. (PMID: 32304208)
J Adv Res. 2020 Nov;26:149-159. (PMID: 32837738)
PLoS One. 2020 Dec 10;15(12):e0242958. (PMID: 33301459)
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078. (PMID: 32358960)
Lancet Infect Dis. 2020 Nov;20(11):1233. (PMID: 32679083)
Front Public Health. 2021 Aug 18;9:583377. (PMID: 34490172)
Clin Microbiol Infect. 2020 Sep;26(9):1248-1253. (PMID: 32585353)
PLoS One. 2020 Aug 28;15(8):e0238417. (PMID: 32857823)
Lancet Infect Dis. 2020 Nov;20(11):1231-1232. (PMID: 32530425)
Biosaf Health. 2020 Jun;2(2):57-59. (PMID: 32835209)
JAMA Netw Open. 2020 Jun 1;3(6):e2013075. (PMID: 32573706)
BMJ. 2020 Nov 9;371:m4312. (PMID: 33168522)
BMJ. 2020 Nov 3;371:m4267. (PMID: 33144292)
Bull World Health Organ. 2020 Sep 01;98(9):590-598. (PMID: 33012859)
Int J Infect Dis. 2020 Oct;99:190-192. (PMID: 32745627)
Contributed Indexing:
Keywords: COVID-19; Diagnosis; Mass screening; SARS-CoV-2; Sample pooling
Entry Date(s):
Date Created: 20210418 Date Completed: 20210421 Latest Revision: 20240401
Update Code:
20240401
PubMed Central ID:
PMC8052526
DOI:
10.1186/s12879-021-06061-3
PMID:
33865325
Czasopismo naukowe
Background: The current pandemic of the SARS-CoV-2 virus, widely known as COVID-19, has affected millions of people around the world. The World Health Organization (WHO) has recommended vigorous testing to differentiate SARS-CoV-2 from other respiratory infections to aid in guiding appropriate care and management. Situations like this have demanded robust testing strategies and pooled testing of samples for SARS-CoV-2 virus has provided the solution to mass screening of people for COVID-19. A pooled testing strategy can be very effective in testing when resources are limited, yet it comes with its own limitations. These benefits and limitations need critical consideration when it comes to testing highly infectious diseases like COVID-19.
Methods: This study evaluated the pooled testing of nasopharyngeal swabs for SARS-COV-2 by comparing the sensitivity of individual sample testing with 4-and 8-pool sample testing. Median cycle threshold (Ct) values were compared, and the precision of pooled testing was assessed through an inter- and intra-assay of pooled samples. Coefficient of variance was calculated for inter- and intra-assay variability.
Results: The sensitivity becomes considerably lower when the samples are pooled. There is a high percentage of false negative reports with larger sample pool size and when the patient viral load is low or weak positive samples. High variability was seen in the intra- and inter-assay, especially among weak positive samples and when more number of samples are pooled together.
Conclusion: As COVID - 19 infection numbers and need for testing remain high, we must meticulously evaluate the testing strategy for each country depending on its testing capacity, infrastructure, economic strength, and need to determine the optimal balance on the cost-effective strategy of resource saving and risk/ cost of missing positive patients.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies